Fisetin
OTC flavonoid senolytic. Lower risk than the prescription combination; thinner standalone human evidence.
What it does
An OTC flavonoid senolytic — lower risk than the prescription dasatinib + quercetin combination, but the standalone human efficacy data does not yet exist. A lower regulatory bar is not a lower evidentiary bar.
A flavonoid found in strawberries and other plants, hypothesized to selectively trigger apoptosis in senescent cells via pathways similar to dasatinib + quercetin — studied far less in humans.
What the evidence shows
Overall evidence strength: Very low certainty
Who it's for, who should skip
Experimental. No standardized human dosing protocol exists; research doses (~20 mg/kg for a few consecutive days, pulsed) extrapolate from animal data. Not a validated intervention.
Running it
- Form
- oral
- Cycling
- intermittent pulse dosing; research doses ~20 mg/kg for a few consecutive days, pulsed periodically; no standardized human protocol
Safety
- generally well-tolerated at studied doses; long-term pulse-dosing effects uncharacterized; potency varies across the unregulated market
Stacking & alternatives
Access & cost
Available over the counter. Look for: third-party tested fisetin.
Last reviewed 27 August 2026.